Flamel Technologies S.A. (NASDAQ:AVDL) Releases FY17 Earnings Guidance
Flamel Technologies S.A. (NASDAQ:AVDL) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $0.30-0.45 for the period, compared to the Thomson Reuters consensus estimate of $0.35. The company issued revenue guidance of $165-175 million, compared to the consensus revenue estimate of $177.31 million.
Flamel Technologies S.A. (AVDL) opened at 8.82 on Wednesday. Flamel Technologies S.A. has a 1-year low of $8.40 and a 1-year high of $15.45. The stock has a 50 day moving average price of $10.38 and a 200 day moving average price of $10.02. The firm’s market capitalization is $364.94 million.
Flamel Technologies (NASDAQ:AVDL) last issued its earnings results on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.14. Flamel Technologies had a positive return on equity of 14.49% and a negative net margin of 7.28%. The company had revenue of $46.30 million for the quarter, compared to analyst estimates of $45.17 million. Flamel Technologies’s revenue was up 19.0% on a year-over-year basis. Analysts predict that Flamel Technologies S.A. will post $0.54 EPS for the current year.
Separately, Zacks Investment Research raised Flamel Technologies from a hold rating to a buy rating and set a $12.00 target price on the stock in a research report on Monday, July 17th.
In other news, Director Guillaume Cerutti sold 26,560 shares of the stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $10.46, for a total transaction of $277,817.60. Following the transaction, the director now owns 23,440 shares of the company’s stock, valued at approximately $245,182.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of the stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $10.68, for a total value of $2,787,480.00. The disclosure for this sale can be found here. Corporate insiders own 5.07% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/09/flamel-technologies-s-a-nasdaqavdl-releases-fy17-earnings-guidance.html.
About Flamel Technologies
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.